title: Neutralization of feline infectious peritonitis virus: preparation of monoclonal antibody that shows cell tropism in neutralizing activity after viral absorption into the cells.
abstract: Feline infectious peritonitis virus (FIPV) infection of feline macro-phages is enhanced by mouse anti-FIPV monoclonal antibody (MAb). This anti-body-dependent enhancement (ADE) of FIPV infection is dependent on mouse MAb subclass, and MAb of IgG2a subclass has a strong ADE activity. Furthermore, MAb showing strong neutralizing activity in Felis catus whole fetus (fcwf-4) cells and Crandell feline kidney (CrFK) cells shows strong enhancing activity in feline macrophages, indicating that the neutralizing epitope and the enhancing epitope are closely related. In this study, we prepared MAb FK50-4 that showed a strong neutralizing activity in feline macrophages, despite the fact that the MAb belonged to the IgG2a subclass. However, MAb FK50-4 did not exhibit neutralizing activity in CrFK cells or fcwf-4 cells, thus showing a very unusual property. MAb FK50-4 recognized FIPV small integral membrane glycoprotein (M protein). Even when feline macrophages were pretreated with MAb FK50-4 prior to FIPV inoculation, this antibody prevented FIPV infection. This reaction disappeared after treatment of FK50-4 with protein A. The neutralizing activity of FK50-4 was also effective on feline macrophages after the cells were inoculated with FIPV. These findings indicated that the FIPV replication mechanism differs between feline macrophages and CrFK/fcwf-4 cells and that a neutralizing epitope that can prevent FIPV infection of feline macrophages after viral absorption is present on M protein.
authors.affiliation: Department of Veterinary Infectious Diseases, School of Veterinary Medicine and Animal Sciences, Kitasato University, Towada, Aomori, Japan.
authors.forename: K
authors.initials: K
authors.lastname: Kida
authors.forename: T
authors.initials: T
authors.lastname: Hohdatsu
authors.forename: J
authors.initials: J
authors.lastname: Kashimoto-Tokunaga
authors.forename: H
authors.initials: H
authors.lastname: Koyama
mesh_terms: D000042:Absorption; D000818:Animals; D000911:Antibodies, Monoclonal / Q000096:biosynthesis / Q000276:immunology*; D000914:Antibodies, Viral / Q000096:biosynthesis / Q000276:immunology*; D000918:Antibody Specificity; D019067:Antibody-Dependent Enhancement; D015153:Blotting, Western; D002415:Cats; D002460:Cell Line; D016765:Coronavirus, Feline / Q000276:immunology* / Q000502:physiology; D005347:Fibroblasts; D019084:Fluorescent Antibody Technique, Indirect; D006825:Hybridomas; D007074:Immunoglobulin G / Q000276:immunology; D016676:Macrophages, Alveolar / Q000821:virology*; D051379:Mice; D009500:Neutralization Tests; D014763:Viral Matrix Proteins / Q000276:immunology
chemical_list: D000911:Antibodies, Monoclonal; D000914:Antibodies, Viral; D007074:Immunoglobulin G; D014763:Viral Matrix Proteins